Table 4

Performance assessment of C2Maps in varying cancers.

Bladder

Breast

Leukemia

Lung

Lymphoma

Melanoma

Ovary

Pancreas

Prostate

Sensitivity

80.84%

79.80%

83.16%

78.44%

81.20%

77.39%

80.88%

84.99%

82.84%


Specificity

87.11%

84.91%

86.11%

89.37%

87.60%

91.53%

84.34%

86.45%

88.38%

ACC

86.70%

84.27%

85.63%

87.86%

86.78%

90.17%

84.09%

86.34%

87.93%


PPV

30.51%

43.01%

53.39%

54.06%

48.92%

49.24%

28.84%

33.82%

38.88%

F-Score

44.30%

55.89%

65.03%

64.01%

61.05%

60.19%

42.52%

48.38%

52.92%


The experiment were performed using a protein interaction confidence minimum threshold of 3 star and above (i.e., reliability score of >0.75) and retrieved drug p-value at a minimum threshold of 0.05. The detailed evaluation procedures and measurement definitions, they can be found in the "Method FAQ" page of our C2Maps website and as supplemental materials.

Huang et al. BMC Genomics 2012 13(Suppl 6):S17   doi:10.1186/1471-2164-13-S6-S17

Open Data